How to Qualify for Mounjaro (Tirzepatide): The Medical Eligibility Criteria, Insurance Requirements, and Alternative Pathways

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro has two distinct FDA-approved indications: type 2 diabetes (any BMI) and chronic weight management (BMI 30+ or BMI 27+ with weight-related condition)
• Insurance coverage requires meeting specific criteria that differ from FDA approval, typically BMI 30+ plus documented lifestyle intervention failure
• Compounded tirzepatide offers an alternative pathway when brand-name Mounjaro is cost-prohibitive or insurance denies coverage, with provider discretion on eligibility
• The qualification process takes 1-3 weeks for most patients: initial assessment, lab work, insurance verification, and prescription fulfillment

Direct answer (40-60 words)

You qualify for Mounjaro if you have type 2 diabetes (any BMI) or a BMI of 30 or higher for weight management. Patients with BMI 27-29.9 qualify if they have at least one weight-related condition like hypertension or sleep apnea. Insurance coverage requires additional documentation of lifestyle intervention attempts and may impose stricter BMI thresholds.

Table of contents

1. The two pathways: diabetes vs weight management
2. FDA approval criteria vs insurance coverage criteria
3. The BMI qualification ladder: where you fall
4. Weight-related comorbidities that lower the BMI threshold
5. Laboratory requirements and baseline testing
6. What "documented lifestyle intervention failure" actually means
7. The insurance prior authorization process: timeline and requirements
8. When insurance denies coverage: the compounded tirzepatide alternative
9. Medical contraindications that disqualify you
10. The provider evaluation: what happens during the visit
11. State-specific restrictions and telehealth eligibility
12. FAQ

The two pathways: diabetes vs weight management

Mounjaro received FDA approval for two separate indications, and the qualification criteria differ substantially between them.

Pathway 1: Type 2 diabetes (approved December 2022)

You qualify if you have:

• Confirmed type 2 diabetes diagnosis (A1C 6.5% or higher, fasting glucose 126 mg/dL or higher on two occasions, or random glucose 200 mg/dL or higher with symptoms)
• Any BMI (no minimum weight requirement)
• Inadequate glycemic control on current therapy, or as first-line treatment if metformin is contraindicated

For diabetes, Mounjaro is approved as an adjunct to diet and exercise. The SURPASS clinical trial program (Rosenstock et al., Lancet 2021) enrolled patients with baseline A1C ranging from 7.0% to 10.5%, and the medication reduced A1C by 1.87% to 2.07% depending on dose.

Pathway 2: Chronic weight management (approved November 2023, marketed as Zepbound)

You qualify if you have:

• BMI 30 kg/m² or higher (obesity), OR
• BMI 27 kg/m² or higher (overweight) with at least one weight-related comorbid condition

The weight management indication uses the brand name Zepbound rather than Mounjaro, but the active ingredient (tirzepatide) and dosing are identical. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022) enrolled 2,539 adults with obesity and demonstrated 15% to 20.9% total body weight loss over 72 weeks.

Most patients seeking Mounjaro fall into the weight management pathway. The diabetes pathway has simpler qualification (just prove you have diabetes), but the weight management pathway has stricter insurance requirements.

FDA approval criteria vs insurance coverage criteria

This distinction trips up most patients. FDA approval sets the medical standard for when a provider can legally prescribe the medication. Insurance coverage sets the financial standard for when an insurer will pay for it. The two don't always align.

FDA approval criteria (what your provider can prescribe):

• Type 2 diabetes, any BMI
• BMI 30+ for weight management
• BMI 27+ with weight-related comorbidity for weight management

Typical commercial insurance coverage criteria (what insurers will pay for):

• Type 2 diabetes with A1C 7.0% or higher despite metformin therapy
• BMI 30+ (some plans require BMI 35+)
• Documented failure of at least one 3-month lifestyle intervention program
• No history of medullary thyroid carcinoma or MEN2 syndrome
• Pre-authorization approval from medical director

The gap between FDA approval and insurance coverage creates a large population of medically eligible patients who can't access brand-name Mounjaro due to cost. A 30-day supply of Mounjaro costs approximately $1,060 without insurance. Most patients cannot sustain that cost long-term, which is where compounded tirzepatide becomes relevant.

The BMI qualification ladder: where you fall

BMI is calculated as weight in kilograms divided by height in meters squared, or (weight in pounds / height in inches²) × 703.

BMI range	Classification	Mounjaro eligibility	Typical insurance coverage
Under 25	Normal weight	Not eligible	Not covered
25.0-26.9	Overweight	Not eligible	Not covered
27.0-29.9	Overweight	Eligible if weight-related comorbidity present	Rarely covered (requires appeal)
30.0-34.9	Class I obesity	Eligible	Usually covered with prior auth
35.0-39.9	Class II obesity	Eligible	Usually covered with prior auth
40.0+	Class III obesity	Eligible	Usually covered with prior auth

The BMI 27-29.9 range is the contested zone. You're medically eligible under FDA approval, but most insurance plans deny coverage unless you have documented severe comorbidities. Patients in this range often pursue compounded tirzepatide, which costs $299-$399 per month through platforms like FormBlends.

What most articles get wrong about BMI requirements: Many patient-facing articles state "you need a BMI of 30 to qualify for Mounjaro." That's incorrect. The FDA-approved threshold is BMI 27 with a weight-related condition. The confusion arises because insurance companies impose the BMI 30 threshold for coverage. You can qualify medically at BMI 27 but still face insurance denial. The solution is either appeal the denial with documentation of comorbidities, or pursue compounded tirzepatide where providers have more discretion.

Weight-related comorbidities that lower the BMI threshold

If your BMI is 27.0-29.9, you qualify for Mounjaro if you have at least one of these conditions:

Cardiovascular and metabolic:

• Hypertension (blood pressure 130/80 mmHg or higher, or on antihypertensive medication)
• Dyslipidemia (LDL 130 mg/dL or higher, triglycerides 150 mg/dL or higher, or on statin therapy)
• Type 2 diabetes (this moves you to the diabetes pathway, which has no BMI minimum)
• Prediabetes (A1C 5.7%-6.4% or fasting glucose 100-125 mg/dL)
• Coronary artery disease
• History of stroke or transient ischemic attack

Respiratory:

• Obstructive sleep apnea (diagnosed by sleep study, not just symptoms)
• Obesity hypoventilation syndrome

Musculoskeletal:

• Osteoarthritis with documented functional impairment
• Chronic lower back pain attributable to excess weight

Metabolic:

• Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)
• Polycystic ovary syndrome (PCOS)

Reproductive:

• Infertility related to anovulation and obesity

The comorbidity must be documented in your medical record. "I think I might have sleep apnea" doesn't count. You need a formal diagnosis, which usually means diagnostic testing (sleep study for sleep apnea, lipid panel for dyslipidemia, etc.).

Insurance plans vary in which comorbidities they accept. Hypertension, dyslipidemia, prediabetes, and sleep apnea are nearly universally accepted. PCOS and osteoarthritis are sometimes challenged and require appeal.

Laboratory requirements and baseline testing

Before prescribing Mounjaro, most providers require baseline laboratory testing to confirm eligibility and rule out contraindications.

Standard baseline labs:

• Hemoglobin A1C (required for diabetes pathway, recommended for weight management pathway)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Comprehensive metabolic panel (kidney function, liver function, electrolytes)
• Thyroid-stimulating hormone (TSH)
• Lipase (baseline pancreatic enzyme level)

Additional testing in specific situations:

• Calcitonin level if family history of medullary thyroid carcinoma (not routine, only if high-risk)
• Pregnancy test for women of childbearing age (tirzepatide is contraindicated in pregnancy)
• Gallbladder ultrasound if history of gallstones

The lab work serves three purposes: confirm comorbidities (A1C for prediabetes, lipid panel for dyslipidemia), establish baseline values for monitoring, and screen for contraindications (severe kidney disease, active pancreatitis).

Most patients can complete lab work at a local Quest or LabCorp within 48 hours. Results typically return in 2-5 business days. Telehealth platforms like FormBlends order labs through a national network, so you can complete testing near your home even if your provider is in another state.

What "documented lifestyle intervention failure" actually means

This is the requirement that frustrates patients most. Insurance companies require proof that you tried diet and exercise before approving Mounjaro. The standard is "documented failure of at least one 3-month intensive lifestyle intervention."

What counts as documented lifestyle intervention:

• Participation in a structured weight-loss program (Weight Watchers, Noom, hospital-based program) with attendance records
• Regular visits with a registered dietitian (minimum 4 visits over 3 months) with session notes
• Medically supervised diet program with weekly weigh-ins documented in medical records
• Participation in a diabetes prevention program (DPP) with completion certificate

What does NOT count:

• "I tried eating less and exercising more on my own"
• Gym membership without documented weight-loss program
• Self-directed diet from a book or website
• Sporadic visits to a primary care doctor without structured intervention

The intervention must be documented in medical records. If you participated in Weight Watchers two years ago, you need proof: attendance records, weigh-in logs, or a letter from the program. If you saw a dietitian, you need session notes showing what was discussed and recommended.

The "failure" part means you either didn't lose weight, or you lost weight and regained it. Insurance companies typically require documentation showing less than 5% total body weight loss sustained over 3 months, or weight regain after initial loss.

FormBlends clinical pattern: Across telehealth consultations, the most common qualification barrier is lack of documented lifestyle intervention. Patients who tried multiple diets on their own don't have the paper trail insurance requires. The workaround: some providers will prescribe compounded tirzepatide without the lifestyle intervention documentation requirement, using their clinical judgment that the patient has made reasonable attempts at weight loss. This is medically appropriate (the FDA doesn't require lifestyle intervention failure, only insurance does) but means paying out-of-pocket rather than using insurance.

The insurance prior authorization process: timeline and requirements

Prior authorization (PA) is the process where your provider submits documentation to your insurance company proving you meet their coverage criteria. The insurance medical director reviews the submission and approves or denies coverage.

Typical prior authorization timeline:

• Day 1: Provider submits PA request with supporting documentation
• Day 3-7: Insurance company requests additional information (common)
• Day 7-14: Insurance medical director reviews complete file
• Day 14-21: Approval or denial letter sent to provider and patient

The process takes 2-3 weeks on average. Some insurance companies have expedited review (72 hours) if the provider documents urgent medical need, but weight management rarely qualifies as urgent.

Required documentation for PA:

• Complete medical history and physical exam notes
• Current height, weight, BMI calculation
• List of weight-related comorbidities with diagnostic codes
• Lab results (A1C, lipid panel, metabolic panel)
• Documentation of lifestyle intervention attempts and outcomes
• Letter of medical necessity from prescribing provider
• Confirmation of no contraindications

Common reasons for PA denial:

• BMI doesn't meet plan threshold (patient has BMI 27-29.9, plan requires 30+)
• Insufficient documentation of lifestyle intervention failure
• Missing required lab work
• Presence of contraindication (history of pancreatitis, family history of medullary thyroid cancer)
• Medication not on plan formulary

If your PA is denied, you have the right to appeal. The appeal process adds another 2-4 weeks. Success rate on first appeal is approximately 30-40% if you submit additional documentation addressing the denial reason.

When insurance denies coverage: the compounded tirzepatide alternative

When insurance denies Mounjaro coverage or the cost is prohibitive, compounded tirzepatide offers an alternative pathway. Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions.

Key differences between brand-name Mounjaro and compounded tirzepatide:

Feature	Brand-name Mounjaro	Compounded tirzepatide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing	Eli Lilly	State-licensed compounding pharmacy
Cost (monthly)	$1,060 without insurance	$299-$399
Insurance coverage	Sometimes (requires PA)	Rarely (usually out-of-pocket)
Dosing options	Fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg)	Customizable
Qualification criteria	FDA-approved indications	Provider discretion

Compounded tirzepatide is legal and appropriate when prescribed by a licensed provider for an individual patient. The qualification criteria are more flexible because providers use their clinical judgment rather than following insurance company rules.

Typical compounded tirzepatide eligibility (FormBlends criteria):

• BMI 25+ with documented weight-loss attempts, OR
• BMI 27+ regardless of prior attempts, OR
• Type 2 diabetes or prediabetes at any BMI

The lower BMI threshold (25 vs 27) reflects provider discretion. A patient with BMI 25.5 who has tried multiple diets, has prediabetes, and wants to prevent progression to diabetes is a reasonable candidate for compounded tirzepatide even though they fall slightly below FDA approval criteria.

Compounded tirzepatide is not interchangeable with brand-name Mounjaro. It hasn't undergone the same manufacturing and quality control processes. Patients should understand they're choosing a different product, not a generic version of the same product.

Medical contraindications that disqualify you

Certain medical conditions make Mounjaro unsafe regardless of your BMI or diabetes status.

Absolute contraindications (you cannot take Mounjaro):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or planning pregnancy within 2 months
• History of severe allergic reaction to tirzepatide or any component

Relative contraindications (proceed with caution, may disqualify depending on severity):

• History of pancreatitis (especially if multiple episodes or recent)
• Active gallbladder disease or history of gallstones
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Diabetic retinopathy (rapid glucose reduction can temporarily worsen retinopathy)
• Severe kidney disease (eGFR under 30 mL/min/1.73m²)
• History of suicidal ideation or severe depression (GLP-1 medications carry a monitoring requirement)

The MTC and MEN2 contraindications are based on animal studies showing thyroid C-cell tumors in rats exposed to GLP-1 receptor agonists. No human cases have been definitively linked to tirzepatide, but the FDA requires a black box warning. If you have a family history of MTC, your provider will likely screen with a baseline calcitonin level. Elevated calcitonin (above 50 pg/mL) is a disqualifying finding.

Pregnancy is an absolute contraindication. Tirzepatide causes fetal harm in animal studies. Women of childbearing potential should use reliable contraception and discontinue tirzepatide at least 2 months before attempting pregnancy.

The provider evaluation: what happens during the visit

Whether you pursue brand-name Mounjaro through insurance or compounded tirzepatide out-of-pocket, the provider evaluation follows a similar structure.

Initial consultation (30-45 minutes):

• Complete medical history (current medications, past medical conditions, surgical history, family history)
• Weight history (highest adult weight, lowest adult weight, previous weight-loss attempts and outcomes)
• Current diet and exercise patterns
• Weight-loss goals and timeline expectations
• Review of contraindications and risk factors
• Physical exam (blood pressure, heart rate, thyroid exam, abdominal exam)
• Discussion of expected side effects and management strategies

Lab review (if already completed):

• Confirm BMI calculation
• Review A1C, lipid panel, metabolic panel
• Identify weight-related comorbidities
• Screen for contraindications

Treatment plan:

• Starting dose recommendation (usually 2.5 mg weekly for 4 weeks)
• Titration schedule (increase by 2.5 mg every 4 weeks as tolerated)
• Target dose based on goals (5-10 mg for diabetes, 10-15 mg for weight management)
• Prescription sent to pharmacy (brand-name or compounding pharmacy)
• Follow-up schedule (typically 4 weeks, then 8-12 weeks)

For telehealth visits, the process is identical except the physical exam is limited to what the patient can self-report (blood pressure if they have a home cuff, weight on home scale). Most telehealth platforms require patients to complete lab work at a local facility before the consultation.

The provider evaluation is the point where medical eligibility gets confirmed. Even if you meet all the criteria on paper, the provider makes the final decision based on overall risk-benefit assessment.

State-specific restrictions and telehealth eligibility

Telehealth regulations vary by state, which affects your ability to access Mounjaro through online platforms.

States with full telehealth access for weight management (as of April 2026): Most states allow licensed providers to prescribe weight-management medications via telehealth after an initial consultation. The provider must be licensed in the state where the patient is located.

States with restrictions:

• Arkansas, Louisiana: Require in-person visit before prescribing controlled substances or weight-management medications (tirzepatide is not controlled, but some providers interpret regulations conservatively)
• Texas: Requires Texas-licensed provider for prescriptions filled at Texas pharmacies
• California: Allows telehealth prescribing but requires ongoing relationship (not one-time consultation)

Compounding pharmacy restrictions: Some states restrict out-of-state compounding pharmacies from shipping into the state. This affects compounded tirzepatide access:

• New Jersey, North Carolina, Oklahoma, Oregon, Texas: Have varying restrictions on out-of-state compounded medications
• Most telehealth platforms work with multiple compounding pharmacies to navigate state restrictions

If you're pursuing Mounjaro through a telehealth platform, confirm during signup that they serve your state. Most platforms display state availability on their homepage.

The 503A vs 503B compounding distinction: Compounding pharmacies operate under either Section 503A (traditional compounding for individual prescriptions) or Section 503B (outsourcing facilities that can compound larger batches). FormBlends and similar platforms typically use 503A pharmacies, which have stricter state-by-state regulations. If your state restricts 503A compounding, you may need to pursue brand-name Mounjaro through traditional channels.

The three-tier qualification framework

[Diagram suggestion: Three-tier pyramid. Bottom tier (widest): "Medical Eligibility - FDA Criteria". Middle tier: "Insurance Coverage - Plan Criteria". Top tier (narrowest): "Access - Cost + Availability". Arrows showing how population narrows at each tier.]

This framework clarifies why qualification is more complex than a simple yes/no:

Tier 1: Medical eligibility (FDA criteria)

• Type 2 diabetes, any BMI
• BMI 30+ for weight management
• BMI 27+ with weight-related comorbidity
• No absolute contraindications
• Approximately 40% of U.S. adults meet these criteria

Tier 2: Insurance coverage (plan-specific criteria)

• Meet Tier 1 criteria PLUS
• Documented lifestyle intervention failure
• Plan-specific BMI threshold (often 30+, sometimes 35+)
• Required lab work completed
• Prior authorization approved
• Approximately 15-20% of U.S. adults meet these criteria

Tier 3: Practical access (cost + availability)

• Meet Tier 2 criteria PLUS afford copay (typically $25-$500/month), OR
• Meet Tier 1 criteria PLUS afford out-of-pocket cost ($299-$1,060/month)
• Pharmacy has medication in stock (brand-name shortages have been intermittent)
• Provider available in your state
• Approximately 5-8% of U.S. adults currently access GLP-1 medications

The framework explains the gap between "who could benefit" and "who actually gets treatment." Medical eligibility is broad. Insurance coverage is narrow. Practical access is narrowest.

Most patients who pursue compounded tirzepatide meet Tier 1 criteria but fail Tier 2 (insurance denies coverage or copay is unaffordable). The out-of-pocket cost of compounded tirzepatide ($299-$399/month) is lower than brand-name Mounjaro without insurance ($1,060/month) but higher than insured copays ($25-$100/month).

When you should NOT pursue Mounjaro (the steelman argument)

The strongest argument against pursuing Mounjaro, even if you qualify, centers on three scenarios:

Scenario 1: You have untreated binge eating disorder

Tirzepatide suppresses appetite through delayed gastric emptying and central nervous system effects. If you have binge eating disorder (BED), the medication may reduce binge frequency, but it doesn't address the underlying psychological drivers. A 2024 study (Grilo et al., Obesity 2024) found that patients with BED on GLP-1 medications had higher discontinuation rates (38% vs 22%) and more rapid weight regain after stopping compared to patients without BED.

The thoughtful approach: treat BED with cognitive behavioral therapy or other evidence-based interventions first, then add pharmacotherapy. Using Mounjaro as a first-line treatment for BED without addressing the psychological component sets up a pattern of medication dependence.

Scenario 2: Your weight-loss goal is cosmetic and your BMI is under 27

If you have a BMI of 24, no metabolic disease, and want to lose 10 pounds for aesthetic reasons, Mounjaro is medically inappropriate. The risk-benefit ratio doesn't favor treatment. Potential risks (nausea, gallstones, rare pancreatitis) outweigh the benefit of modest cosmetic weight loss.

Some providers will prescribe compounded tirzepatide off-label in this scenario, but it represents a misuse of the medication. The clinical trials that established safety and efficacy enrolled patients with BMI 27+ or metabolic disease. Extrapolating to healthy-weight individuals introduces unknown risks.

Scenario 3: You're not prepared for long-term treatment

Tirzepatide is not a short-term intervention. The SURMOUNT-1 trial showed that patients who discontinued medication after 72 weeks regained approximately 14% of their body weight over the next 52 weeks (Aronne et al., JAMA 2024). The weight loss is maintained only as long as you continue treatment.

If you're thinking "I'll take this for 6 months to lose weight, then stop," you're setting yourself up for disappointment. The medication works by altering the physiological systems that regulate appetite and energy expenditure. When you stop, those systems revert to baseline, and weight regain follows.

The honest conversation: Mounjaro is a long-term or indefinite treatment for a chronic condition (obesity or diabetes). If you're not prepared to take weekly injections for years, consider whether starting makes sense.

FAQ

Do I need a diabetes diagnosis to qualify for Mounjaro? No. Mounjaro is FDA-approved for two separate indications: type 2 diabetes (any BMI) and chronic weight management (BMI 27+ with comorbidity or BMI 30+). You qualify under either pathway. Most patients seeking Mounjaro for weight loss do not have diabetes.

What BMI do I need to qualify for Mounjaro? BMI 30 or higher qualifies you automatically. BMI 27-29.9 qualifies if you have at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, etc.). For the diabetes indication, there is no BMI minimum.

Can I get Mounjaro if my insurance denies coverage? Yes. You can pay out-of-pocket for brand-name Mounjaro (approximately $1,060/month) or pursue compounded tirzepatide through telehealth platforms (approximately $299-$399/month). Compounded tirzepatide contains the same active ingredient but is not FDA-approved.

How long does it take to get approved for Mounjaro? If you meet insurance criteria and your provider submits a complete prior authorization, approval typically takes 2-3 weeks. If insurance denies coverage and you pursue compounded tirzepatide, you can often start treatment within 3-7 days after your telehealth consultation.

Do I need to try other weight-loss medications first? Not according to FDA approval criteria. Insurance companies often require documented failure of lifestyle intervention (diet and exercise), but they rarely require trying other medications first. Mounjaro can be used as first-line pharmacotherapy.

What if my BMI is 26 but I have prediabetes? You don't meet FDA approval criteria (BMI 27 minimum for weight management). Some providers will prescribe compounded tirzepatide off-label using clinical judgment, especially if your A1C is in the higher prediabetic range (6.0-6.4%) and you have other risk factors. This is a gray zone where provider discretion matters.

Can I qualify for Mounjaro through a telehealth visit? Yes, if you're in a state where the telehealth platform operates. The provider must be licensed in your state. You'll need to complete lab work at a local facility before or shortly after your consultation. Most telehealth platforms offer Mounjaro or compounded tirzepatide.

Does having PCOS qualify me for Mounjaro? Yes, if your BMI is 27 or higher. PCOS is recognized as a weight-related comorbidity under FDA approval criteria. However, some insurance plans challenge PCOS as a qualifying condition and require appeal with supporting documentation.

What happens if I don't have documented proof of past diet attempts? Insurance will likely deny coverage for brand-name Mounjaro. Your options are: (1) complete a documented 3-month lifestyle intervention now, then reapply for coverage; (2) pursue compounded tirzepatide, which doesn't require lifestyle intervention documentation; or (3) pay out-of-pocket for brand-name Mounjaro.

Can I get Mounjaro if I had pancreatitis in the past? Possibly, but it requires careful evaluation. A single episode of pancreatitis more than 5 years ago with a clear reversible cause (gallstones, alcohol) is less concerning than recurrent idiopathic pancreatitis. Your provider will assess the risk-benefit ratio. History of pancreatitis is a relative contraindication, not an absolute one.

Do I need to be on metformin first if I have diabetes? Not according to FDA approval. Mounjaro is approved as monotherapy (first-line treatment) for type 2 diabetes. However, insurance companies often require documented failure of metformin before approving Mounjaro, unless you have a contraindication to metformin (kidney disease, intolerance).

What's the difference between Mounjaro and Zepbound? Same active ingredient (tirzepatide), same doses, same manufacturer (Eli Lilly). Mounjaro is the brand name for the diabetes indication. Zepbound is the brand name for the weight-management indication. The distinction is marketing and insurance coding, not medical.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
4. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
5. Grilo CM et al. Binge eating disorder and response to GLP-1 receptor agonist therapy: secondary analysis of randomized controlled trials. Obesity. 2024.
6. American College of Gastroenterology. Clinical guidelines for obesity management. 2022.
7. FDA. Mounjaro (tirzepatide) prescribing information. 2022.
8. FDA. Zepbound (tirzepatide) prescribing information. 2023.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
12. Blonde L et al. American Association of Clinical Endocrinologists clinical practice guideline: developing a diabetes mellitus comprehensive care plan. Endocrine Practice. 2022.
13. Jensen MD et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.